Mumbai, Feb. 28 -- Aurobindo Pharma has completed the acquisition of 80% stake in Tergene Biotech, a step-down subsidiary of the company and also a joint venture company, held by Auro Vaccines, a wholly owned stepdown subsidiary of the company. With this, with effect from 26 February 2025, Tergene has become a direct subsidiary of the company.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.